Page 13 of the presentation:
"Monepantel displays a superior safety, tolerability and preliminary efficacy profile to the leading FDA
approved drug Relyvrio®"
This is probably as good as it gets at phase 1. Better then I thought especially with the life expectancy.
Key takeaway being 13.5-56.5 months additional life expectancy compared to Relyvrio 8-9 months?
Seminar about to start.
Ann: Presentation - Phase 1 Top-Line Results, page-7
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.030(12.8%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 20.5¢ | $276.8K | 1.274M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134649 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 65000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.0¢ |
Change
-0.030 ( 8.70 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 23.0¢ | 21.0¢ | 615701 | ||
| Last updated 15.56pm 06/06/2024 ? | |||||
| PAA (ASX) Chart |